Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2253 • ACR Convergence 2025
Wrist-worn Wearable Device Data Can Be a New Digital Biomarker For Disease Activity In Rheumatoid Arthritis: a Multicenter Single-arm Prospective Study
Misako Higashida-Konishi¹, Keisuke Izumi², Shuntaro Saito Saito³, Hiroki Tabata⁴, Satoshi Hama⁴, Tatsuhiro Oshige⁴, Yutaka Okano⁴, Hisaji Oshima⁴, Katsuya Suzuki⁴, Jiro Sakamoto⁵, Toshikazu Fukami⁵, Kazumichi Minato⁵, Nobuhiko Kajio⁶, Yasushi Kondo³, Hiroaki Taguchi⁶ and Yuko Kaneko³, ¹NHO Tokyo Medical Center, Tokyo Meguroku, Japan, ²Division of Rheumatology, Department of Medicine, NHO Tokyo Medical Center/Keio University School of Medicine/TechDoctor, Inc., Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Medicine, NHO Tokyo Medical Center, Tokyo, Japan, ⁵TechDoctor, Inc., Tokyo, Japan, ⁶Department of Rheumatology, Kawasaki Municipal Hospital, Kanagawa, Japan
Background/Purpose: Previous studies have estimated physical and mental states using wearable device data such as from smartwatches [1–3]. This study aimed to identify digital biomarkers…
Abstract Number: 2236 • ACR Convergence 2025
Treatment-induced autoantibodies in Rheumatoid Arthritis patients receiving anti-TNF inhibitors or JAK inhibitors
EVRIPIDIS KALTSONOUDIS¹, Nikolaos Kougkas², Panagiota Karagianni³, Tereza Memi⁴, Nikolaos Koletsos⁵ and Eleftherios Pelechas⁶, ¹Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ²⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ³BioAcuHealth.gr, Ioannina, Ioannina, Greece, ⁴University Hospital of Ioannina, Ioannina, Ioannina, Greece, ⁵School of Health Sciences, Faculty of Medicine, University of Ioannina, Department of Rheumatology, Ioannina, Greece, Ioannina, Ioannina, Greece, ⁶Hatzikosta General Hospital of Ioannina, Ioannina, Ioannina, Greece
Background/Purpose: Rheumatoid arthritis (RA) can coexist with other autoimmune disorders such as Sjögren’s syndrome and systemic lupus erythematosus (SLE). In these cases, the terms secondary…
Abstract Number: 2166 • ACR Convergence 2025
Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis: A Clinical Educational Workshop
Ahmed Rubia¹, Nancy Olsen², Saurav Suman³, Sharon Banks⁴, Shirley Albano Aluquin¹, Kristie Pepper⁵ and Rayford June⁶, ¹Penn State Milton S. Hershey Medical Cen, Hershey, PA, ²Penn State University/Milton S Hershey, Hershey, PA, ³Penn State Milton S. Hershey Medical Cen, Harrisburg, PA, ⁴Penn State Milton S. Hershey Medical Center, Hershey, PA, ⁵Penn State Milton S. Hershey Medical Cen, Lebanon, PA, ⁶Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA
Background/Purpose: The Clinical Disease Activity Index (CDAI) is one of six assessment measures for rheumatoid arthritis (RA) recommended for management of RA in clinical practice.…
Abstract Number: 1932 • ACR Convergence 2025
Evaluating a Potential Cause of Excess Lung Cancer Mortality in RA: An Analysis of Chest CT Imaging Frequency in RA
Rebecca Brooks¹, Sara Achenbach², Vanessa Kronzer¹, Bryant England³, Emily Leasure¹, Elena myasoedova¹, John Davis¹ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³University of Nebraska Medical Center, Omaha, NE, ⁴Mayo Clinic, Stewartvillle, MN
Background/Purpose: Recent studies have demonstrated that patients with RA are at an increased risk for the development of lung cancer and lung cancer related death.…
Abstract Number: 1750 • ACR Convergence 2025
Urinary Proteomic Signature Identifies Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Jia Shi¹, Xueting Yuan², Yafang Deng³, Chen Yu⁴, Nan Jiang⁵, Zhengguang Guo⁶, Christian Lood⁷, Mengtao Li⁵, Wei Sun⁶, Qian Wang⁵ and Xinping Tian⁵, ¹University of Washington, Seattle, WA, ²Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ³Peking Union Medical College Hospital. Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China (People's Republic), ⁴Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁵Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁶Peking Union Medical College, Beijing, China (People's Republic), ⁷University of Washington, Division of Rheumatology, Seattle
Background/Purpose: Interstitial lung disease (ILD) is a serious pulmonary complication of rheumatoid arthritis (RA), contributing significantly to morbidity and mortality. Non-invasive tools for identifying ILD…
Abstract Number: 1678 • ACR Convergence 2025
Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study
Andrew Cope¹, Joana Vasconcelos¹, Marianna Jasenecova², Andrew Filer³, Karim Raza⁴, Sumera Qureshi¹, Maria Antonietta D'Agostino⁵, Iain McInnes⁶, Stefan Siebert⁶, John Isaacs⁷, Arthur Pratt⁸, Benjamin A. Fisher⁹, Christopher Buckley¹⁰, Paul Emery¹¹, Kulveer Mankia¹¹, Pauline Ho¹², MAYA BUCH¹³, Coziana Ciurtin¹⁴, Dirkjan van Schaardenburg¹⁵, Tom Huizinga¹⁶, René Toes¹⁶, Caroline Murphy¹ and A. Toby Prevost¹, ¹King's College London, London, United Kingdom, ²King's College London, London, ³The University of Birmingham, Birmingham, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷Newcastle University, Newcastle upon Tyne, United Kingdom, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, ¹⁰University of Oxford, Oxford, United Kingdom, ¹¹University of Leeds, Leeds, England, United Kingdom, ¹²The Kellgren Centre for Rheumatology, Manchester Royal Infirmary, Manchester, United Kingdom, ¹³UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ¹⁴University College London, London, ¹⁵Amsterdam UMC, Amsterdam, Netherlands, ¹⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Clinical trials aimed at delaying or preventing rheumatoid arthritis (RA) in individuals at risk have been published with variable results. In the APIPPRA study,…
Abstract Number: 1374 • ACR Convergence 2025
AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers
Susanne Prothon¹, Jacob Leander¹, Ulla Seppälä¹, Eduard Molins², Mia Collins¹, Nicholas White³, Ivonne Puente¹, Andre Santa Maria¹, Gary Sims⁴, David Han⁵, Obada Al Hamdan⁶, Ronald Goldwater⁷, Emon Khan⁸ and David Close⁹, ¹AstraZeneca, Gothenburg, Sweden, ²AstraZeneca, Barcelona, Spain, ³AstraZeneca, Cambridge, United Kingdom, ⁴AstraZeneca, Gaithersburg, ⁵Parexel, Los Angeles, ⁶Parexel, Berlin, Germany, ⁷Parexel, Baltimore, ⁸BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom, ⁹AstraZeneca, Royston, United Kingdom
Background/Purpose: AZD1163 is a novel bispecific antibody that inhibits the activity of extracellular Peptidyl Arginine Deiminases (PADs) 2 and 4, enzymes responsible for protein citrullination…
Abstract Number: 1356 • ACR Convergence 2025
Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Jonathan Kay¹, Eugen feist², Ernest Choy³, Joerg Kaufmann⁴, Ernest Wong⁵, Hector Corominas⁶, René-Marc Flipo⁷, Jérôme Avouac⁸, María América López Lasanta⁹, Joelle Monnet¹⁰, Peter Baker¹¹, Maria Romanova Michailidi¹², Fabrizio Dolfi¹¹ and Graziella Pourcel¹³, ¹UMass Chan Medical School, Worcester, MA, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴NA, Ludwigsfelde, Germany, ⁵Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁶Hospital de Sant Pau, Barcelona, Spain, ⁷Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁸Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁹Hospital Universitario Vall d´Hebron, Barcelona, Spain, ¹⁰Fresenius Kabi SwissBioSim, Eysins, Switzerland, ¹¹Fresenius Kabi Biopharma, Eysins, Switzerland, ¹²University of Geneva, Eysins, Switzerland, ¹³Fresenius Kabi Biopharma, Eyzins, France
Background/Purpose: Although most healthcare professionals are convinced of the quality, safety, and favorable economic impact of biosimilars, their routine use is not yet widespread. MSB11456…
Abstract Number: 1340 • ACR Convergence 2025
Does Moderate Alcohol Use Lower Disease Activity Among Patients with Rheumatoid Arthritis?
Sarah Crisci¹, Joshua Baker², Kevin Kane³, George Reed⁴, Dimitrios Pappas⁵ and Joel Kremer⁶, ¹New York University, New York, NY, ²University of Pennsylvania, Philadelphia, PA, ³University of Massachusetts Lowell, Lowell, MA, ⁴University of Massachusetts Chan Medical School, Worcester, MA, ⁵CorEvitas, New York, NY, ⁶The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: The relationship between alcohol use and disease activity among patients with rheumatoid arthritis (RA) remains controversial. Several studies have concluded that moderate drinking may…
Abstract Number: 1323 • ACR Convergence 2025
Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial
Tatiana Lisitsyna¹, Anton Abramkin², Dmitry Veltishchev³, Sofia Kuzkina⁴, Anastasia Borisova², Vasily Ignatiev⁵, Mikhail Samsonov⁶ and Eugeny Nasonov², ¹Thromboinflammation Laboratory of the Department of Systemic Rheumatic Diseases V.A.Nasonova Research Institute of Rheumatology, Moskva, Russia, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³V.A.Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁴R-Pharm, Moscow, Russia, ⁵"R-Pharm", JSC, Moscow, Russia, ⁶RPharm, Brussels, Belgium
Background/Purpose: Interleukin (IL)-6 plays an important role in the pathogenesis of depression in rheumatoid arthritis (RA) patients. IL-6 inhibitors used to treat patients with RA…
Abstract Number: 1306 • ACR Convergence 2025
Systematic Literature Review of Digital Sleep Outcomes and Endpoints Used to Assess Rheumatoid Arthritis
Anna fishbein¹, Rachel Lawson², Veleka Allen¹, Sophie Wilhelm¹, Tracy Zhang³, Leanne Williams¹, Karen Chandross¹, Godhuli Chatterjee⁴, Markus Kohlmann⁵ and Jeffrey Curtis⁶, ¹Sanofi, Morristown, NJ, ²Sanofi, Earley, United Kingdom, ³Sanofi, Waltham, MA, ⁴Sanofi Healthcare India Private Limited, Mumbai, Maharashtra, India, ⁵Sanofi, Frankfurt, Germany, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Sleep disturbances are prevalent among patients with rheumatoid arthritis (RA), posing a substantial burden to patients and are intricately linked to disease activity and…
Abstract Number: 1105 • ACR Convergence 2025
Association between pre-existing rheumatoid arthritis and immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors
Kevin Sheng-Kai Ma¹, You Wu², Rachael Stovall², Jean Liew³ and Namrata Singh⁴, ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²University of Washington, Seattle, WA, ³Boston University, Boston, MA, ⁴University of Washington, Bellevue, WA
Background/Purpose: Immune checkpoint inhibitors (ICIs), widely used to treat a variety of cancers, are associated with immune-related adverse events (irAEs) that are increasingly encountered in…
Abstract Number: 1031 • ACR Convergence 2025
Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021
Satani Sharkas¹, Dina Murad² and Dariush Jahandideh³, ¹Boston Medical Center - Brighton, Brighton, MA, ²Tufts Medical Center, Boston, MA, ³Boston Medical Center - Brighton, Boston
Background/Purpose: Rheumatoid arthritis (RA) is a growing public health concern in the United States, with increasing prevalence and disease burden over recent decades. This study…
Abstract Number: 0928 • ACR Convergence 2025
Radiolabelled anti-citrullinated histone antibody CIT-013 as a tool to visualize NET rich inflamed joints in a collagen induced arthritic mouse model
Annemarie Kip¹, Daphne Dorst², Birgitte Walgreen², Monique Helsen², Eric meldrum¹, Renato Chirivi¹ and Marije Koenders², ¹Citryll BV, Oss, Netherlands, ²RadboudUMC, Nijmegen, Netherlands
Background/Purpose: Neutrophil Extracellular Traps (NETs) contribute to the pathophysiology of multiple immune-mediated inflammatory diseases including Rheumatoid Arthritis (RA), and may be promising therapeutic targets. The…
Abstract Number: 0835 • ACR Convergence 2025
IgG Glycome In Early Rheumatoid Arthritis Differs From Matched Controls and Links Less Lean Mass to an Early Aging Phenotype
Sidra Hashmi¹, Brian Andonian², Mary Ahern³, William Bennett⁴, Alyssa Sudnick⁵, Johanna Johnson⁵, Sridevi Krishnan³ and Kim Huffman⁵, ¹Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA, Morrisville, NC, ²Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA, morrisville, ³University of Arizona, ARIZONA, ⁴Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA, DURHAM, NC, ⁵Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA, Durham
Background/Purpose: Glycosylation is a post-translational enzymatic process important for protein function. Glycosylation patterns range from anti-inflammatory to inflammatory, and have been used to derive a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].